BrainStorm Therapeutics, Inc.
Mark Norman is an accomplished professional in the fields of drug discovery and biotechnology, currently serving as President of Scicon Solutions since January 2016. Scicon Solutions specializes in scientific consulting and contract research services tailored to pharmaceutical and biotech companies. Additionally, Mark holds advisory roles at BrainStorm Therapeutics, Inc. and ADRx, Inc., contributing to innovative research in neurodegenerative diseases. Mark's past experience includes a significant tenure as Scientific Executive Director at Amgen, where groundbreaking therapies were developed, as well as prior roles at GlaxoWellcome and Burroughs Wellcome. Mark has also shared expertise in academia as an Adjunct Organic Chemistry Professor at California Lutheran University. Mark earned a PhD in Organic Chemistry from the University of California, Berkeley, following a BS in Chemistry from the University of New Hampshire.
This person is not in any teams
BrainStorm Therapeutics, Inc.
BrainStorm Therapeutics is developing an all-in-human brain organoid platform that integrates experimental and computational approaches to discover disease-modifying therapies for brain disorders. We engineer brain organoids with mutations known to drive disease and probe them with high-throughput screens to develop AI-driven digital organoid foundation models to identify and validate therapeutic targets and drug candidates that reverse disease progression. Our founding team successfully identified a therapeutic candidate for the rare genetic neurodevelopmental disorder, Rett syndrome, advancing to a Phase 2 clinical trial by screening patient-derived cortical brain organoids. Our first therapeutic programs are focused on rare genetic neurodevelopmental disorders and diseases caused by degeneration or dysfunction of midbrain dopamine neurons, including Parkinson’s disease, schizophrenia, and addiction. Our highly scalable platform can address other complex brain disorders and therapeutic areas.